Essential Thrombocythemia News and Research

RSS
FDA approves new drug to treat patients with myelofibrosis

FDA approves new drug to treat patients with myelofibrosis

People who have a parent, sibling, or child with blood cancer have higher risk of disease

People who have a parent, sibling, or child with blood cancer have higher risk of disease

Potential combination therapy against rare disease of the bone marrow could improve treatment

Potential combination therapy against rare disease of the bone marrow could improve treatment

Detailed structure of protein pair offers blueprint for new medicines

Detailed structure of protein pair offers blueprint for new medicines

Study finds new therapeutic target to prevent progression of rare blood cancer

Study finds new therapeutic target to prevent progression of rare blood cancer

New NCCN Guidelines outline diagnosis, treatment strategies for myeloproliferative neoplasms

New NCCN Guidelines outline diagnosis, treatment strategies for myeloproliferative neoplasms

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Promedior to present interim data from PRM-151 Phase 2 trial at ASCO 2014 Annual Meeting

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

Incyte Corporation publishes results of Phase III trial of ruxolitinib in patients with polycythemia vera

NeoGenomics launches new test for detection of mutations in CALR gene

NeoGenomics launches new test for detection of mutations in CALR gene

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

AMP 2013: EKF Molecular Diagnostics to launch four new PointMan DNA enrichment kits

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Study provides new insight on cancer prevention

Study provides new insight on cancer prevention

Tool reveals myeloproliferative neoplasm patient burden

Tool reveals myeloproliferative neoplasm patient burden